BioNexus Gene Lab Corp. (BGLC) Operating cash flow 2018–2025
BioNexus Gene Lab Corp. (BGLC) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$1.8MFY2025 · since FY2018: -$274,080 → -$1.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$1.8M | +12.2% |
| FY2024 | -$2.1M | -14.9% |
| FY2023 | -$1.8M | -430.2% |
| FY2022 | $551,822 | +5923.6% |
| FY2021 | $9,161 | -98.3% |
| FY2020 | $552,680 | +354.4% |
| FY2019 | -$217,273 | +20.7% |
| FY2018 | -$274,080 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BGLC financial trends
BGLC RevenueBGLC Net incomeBGLC Net marginBGLC Gross profitBGLC Gross marginBGLC Operating incomeBGLC Operating marginBGLC Free cash flowBGLC Capital expendituresBGLC Return on equityBGLC Stock buybacksBGLC Dividends paidBGLC Total assetsBGLC Total liabilitiesBGLC Shareholders’ equityBGLC overview →